A Novel Drug for Borderline Personality Disorder
Borderline Personality Disorder (BPD) is one of the most prevalent psychiatric disorders with high morbidity and mortality. It affects the lives of millions worldwide and is often highly incapacitating, leading to significant psychosocial dysfunction. Moreover, nearly all patients have experienced suicidal ideation and
| Condition(s) | Borderline Personality Disorder |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | Borderline Personality Disorder (BPD) is one of the most prevalent psychiatric disorders with high morbidity and mortality. It affects the lives of millions worldwide and is often highly incapacitating, leading to significant psychosocial dysfunction. Moreover, nearly all patients have experienced suicidal ideation and about 10% actually commit suicide, a rate almost 50 times higher than in the general population. Mostly young women are at greater risk for the disorder and are three times more likely to be diagnosed with BPD than men. BPD aetiology is complex and could be explained by both biological and environmental factors. Among the environmental factors, sexual or physical abuse, parental divorce, loss or illnesses are identified as the most common ones. These factors can induce dysfu |
| Who can participate | Inclusion criteria Participants will be eligible to proceed in the study if they meet all of the following criteria (as determined in the screening session): 1. Men and women aged between 18-65 years of age 2. A current diagnosis of BPD, or a score ≥ 8 on Diagnostic Interview for Borderline patients, or a score ≥ 15 on Zanarini Rating Scale for Borderline Personality Disorder 3. Proficient in reading and writing English Exclusion criteria Potential participants who meet the criteria for any of the following will be excluded from participating in the study: 1. Clinical evidence of acute delirium or severe head injury 2. Epilepsy or other current seizure disorder, history of seizures or convulsions (not including febrile convulsions), or presence of predisposing factors for epilepsy. 3. Clin |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Lead sponsor | The Alfred |
| Locations | Melbourne, Victoria, Australia |
| Start date | 2015-01 |
| NCT ID | NCT02097706 |
| Official listing | https://clinicaltrials.gov/study/NCT02097706 |